全文获取类型
收费全文 | 643篇 |
免费 | 41篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 27篇 |
妇产科学 | 27篇 |
基础医学 | 99篇 |
口腔科学 | 57篇 |
临床医学 | 89篇 |
内科学 | 103篇 |
皮肤病学 | 12篇 |
神经病学 | 36篇 |
特种医学 | 93篇 |
外科学 | 50篇 |
综合类 | 10篇 |
预防医学 | 26篇 |
眼科学 | 4篇 |
药学 | 27篇 |
1篇 | |
肿瘤学 | 20篇 |
出版年
2021年 | 12篇 |
2020年 | 11篇 |
2019年 | 13篇 |
2018年 | 10篇 |
2017年 | 7篇 |
2016年 | 9篇 |
2015年 | 25篇 |
2014年 | 22篇 |
2013年 | 36篇 |
2012年 | 21篇 |
2011年 | 19篇 |
2010年 | 31篇 |
2009年 | 19篇 |
2008年 | 28篇 |
2007年 | 20篇 |
2006年 | 18篇 |
2005年 | 18篇 |
2004年 | 10篇 |
2003年 | 7篇 |
2002年 | 6篇 |
2001年 | 14篇 |
2000年 | 10篇 |
1999年 | 10篇 |
1998年 | 22篇 |
1997年 | 22篇 |
1996年 | 37篇 |
1995年 | 17篇 |
1994年 | 24篇 |
1993年 | 13篇 |
1992年 | 9篇 |
1991年 | 4篇 |
1990年 | 10篇 |
1989年 | 11篇 |
1988年 | 19篇 |
1987年 | 9篇 |
1986年 | 10篇 |
1985年 | 13篇 |
1984年 | 8篇 |
1983年 | 11篇 |
1982年 | 7篇 |
1981年 | 3篇 |
1980年 | 5篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1977年 | 8篇 |
1976年 | 6篇 |
1975年 | 5篇 |
1971年 | 3篇 |
1970年 | 7篇 |
1969年 | 4篇 |
排序方式: 共有685条查询结果,搜索用时 15 毫秒
1.
2.
Golli M; Van Nhieu JT; Mathieu D; Zafrani ES; Cherqui D; Dhumeaux D; Vasile N; Rahmouni A 《Radiology》1994,190(3):741
3.
4.
5.
6.
Inhibition of 2-nitropropane-induced rat liver DNA and RNA damage by benzyl selenocyanate 总被引:5,自引:2,他引:3
We observed that pretreatment of male F344 rats with benzyl selenocyanate,
a versatile organoselenium chemopreventive agent in several animal model
systems, decreases the levels of DNA and RNA modifications produced in the
liver by the hepatocarcinogen 2- nitropropane. To clarify the mechanisms
involved, we pretreated male F344 rats with either benzyl selenocyanate,
its sulfur analog benzyl thiocyanate, phenobarbital or cobalt
protoporphyrin IX; the latter is a depletor of P450. We then determined (1)
the ability of liver microsomes to denitrify 2-nitropropane, (2) effects on
2-nitropropane- induced liver DNA and RNA modifications and (3) amount of
nitrate excreted in rat urine following administration of the carcinogen.
Pretreatment with benzyl selenocyanate or phenobarbital increased the
denitrification activity of liver microsomes by 217 and 765%, respectively,
increased liver P4502B1 by 31- and 435-fold, respectively, decreased the
levels of 2-nitropropane-induced modifications in liver DNA (29-70% and
17-30%, respectively) and RNA (67-85% and 30-50%, respectively), and
increased the 24-h urinary excretion of nitrate by 157 and 209%,
respectively. Pretreatment with benzyl thiocyanate had no significant
effect on any of these parameters. Pretreatment with cobalt protoporphyrin
IX decreased liver P4502B 1 by 87%, decreased the denitrification activity
of liver microsomes by 76%, decreased the 24 h urinary excretion of nitrate
by 88.5%, but increased the extent of 2-nitropropane-induced liver nucleic
acid modifications by 17-67%. These results indicate that the metabolic
sequence from 2-nitropropane to the reactive species causing DNA and RNA
modifications does not involve the removal of the nitro group. Moreover,
they suggest that benzyl selenocyanate inhibits 2-NP-induced liver nucleic
acid modifications in part by increasing its detoxication through induction
of denitrification, although it is evident that other mechanisms must also
be involved.
相似文献
7.
I. O. Skalpe J. F. Bonneville P. Grane C. Gyldenstedt B. Otto D. T. Kristoffersen M. G. Svaland 《European radiology》1998,8(6):1054-1057
The purpose of this study was to evaluate and compare the radiographic efficacy and safety of iodixanol (Visipaque; 270 and
320 mg I/ml) and iohexol (Omnipaque; 300 mg I/ml) in myelography. The study was randomized, double-blind and comparative including
398 patients from five European university clinics. The radiographic visualisation was evaluated as poor, good or excellent.
Adverse events were recorded by interviewing the patients after the myelography, and each patient was given a questionnaire
to be returned after 1 week. In cervical myelography with cervical puncture more films with excellent quality was obtained
after iodixanol 320 mgI/ml compared with iohexol 300 mgI/ml (p = 0.009). Also in lumbar myelography iodixanol 320 mgI/ml compared favourably with iohexol 300 mgI/ml (p = 0.006). The most frequent adverse event was headache, which occurred in 5–35 % of patients during the first 24 h and in
19–61 % within the first 7 days, depending on the centre. There was no difference in frequency and severity of the adverse
effects between the contrast media.
Received 13 March 1997; Revision received 29 December 1997; Accepted 5 January 1997 相似文献
8.
9.
Ingeborg S. Aaberge Philipp Oster Oddveig S. Helland Anne-Cathrine Kristoffersen Ellen Ypma E. Arne H?iby Berit Feiring Hanne N?kleby 《Clinical and Vaccine Immunology : CVI》2005,12(5):599-605
MenBvac and Menjugate are safe and efficacious vaccines. The purpose of this study was to evaluate safety and immunogenicity of the combination (MenB/C) of the lyophilized active components of the conjugated group C vaccine Menjugate when reconstituted with the full liquid group B outer membrane vesicle vaccine MenBvac compared to MenBvac and Menjugate given separately. At 6-week intervals, healthy adults were given one dose of MenB/C followed by two doses of MenBvac (MenB/C group), three doses of MenBvac (MenB group), or one dose of Menjugate and two doses of placebo (MenC group). Injection site reactions were frequent in all groups. However, most reactions were short lasting and mild or moderate in intensity, and the vaccines were found to be well tolerated, with no vaccine-related serious adverse events. MenB/C was immunogenic with regard to both serogroup B and C meningococci. Both the serum bactericidal assay and the enzyme-linked immunosorbent assay analyses showed that the immune responses of the combination vaccine were similar to the immune responses of its separate components MenBvac and Menjugate for both serogroup B and C. In conclusion, the combined MenB/C vaccine is safe and immunogenic. The two vaccines do not interact negatively with each other and can easily be administered in the same syringe. The induced immune responses suggest that the combined vaccine is likely to confer protection against systemic group B disease caused by the vaccine strain as well as against group C meningococcal disease. 相似文献
10.
A model of corrective gene transfer in X-linked ichthyosis 总被引:5,自引:0,他引:5
Freiberg RA; Choate KA; Deng H; Alperin ES; Shapiro LJ; Khavari PA 《Human molecular genetics》1997,6(6):927-933
Single gene recessive genetic skin disorders offer attractive prototypes
for the development of therapeutic cutaneous gene delivery. We have
utilized X-linked ichthyosis (XLI), characterized by loss of function of
the steroid sulfatase arylsulfatase C (STS), to develop a model of
corrective gene delivery to human skin in vivo. A new retroviral expression
vector was produced and utilized to effect STS gene transfer to primary
keratinocytes from XLI patients. Transduction was associated with
restoration of full-length STS protein expression as well as steroid
sulfatase enzymatic activity in proportion to the number of proviral
integrations in XLI cells. Transduced and uncorrected XLI keratinocytes,
along with normal controls, were then grafted onto immunodeficient mice to
regenerate full thickness human epidermis. Unmodified XLI keratinocytes
regenerated a hyperkeratotic epidermis lacking STS expression with
defective skin barrier function, effectively recapitulating the human
disease in vivo. Transduced XLI keratinocytes from the same patients,
however, regenerated epidermis histologically indistinguishable from that
formed by keratinocytes from patients with normal skin. Transduced XLI
epidermis demonstrated STS expression in vivo by immunostaining as well as
a normalization of histologic appearance at 5 weeks post-grafting. In
addition, transduced XLI epidermis demonstrated a return of barrier
function parameters to normal. These findings demonstrate corrective gene
delivery in human XLI patient skin tissue at both molecular and functional
levels and provide a model of human cutaneous gene therapy.
相似文献